Pediatric Endocrinology News

BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.

An oral medication that stimulates the growth hormone secretagogue receptor 1a induced height velocity increases similar to those seen with recombinant human GH for children with pediatric GH deficiency, according to trial data.

BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.

BOSTON — Girls and boys who experienced stress early in life were more likely than those with lower stress scores to use alcohol, nicotine and cannabis by age 13 years, according to a presenter at ENDO 2024.

Children exposed in utero to higher levels of some types of endocrine-disrupting chemicals have a higher risk for developing metabolic syndrome, according to findings published in JAMA Network Open.

Insufficient sleep was tied to poorer cognition and attention in adolescents who were classified as having overweight or obesity based on their BMI compared with those with normal weight, according to a recent study in JAMA Neurology.

Vosoritide was associated with increased annualized height velocity for children with five different genetic causes of short stature, according to study findings.

Most transgender adolescents receiving a gonadotropin-releasing hormone agonist combined with gender-confirming hormone therapy grow to an adult height close to the reference height for their sex assigned at birth, according to study data.

Children with hypochondroplasia had an increase in growth velocity at 1 year of treatment with vosoritide, according to findings from a phase 2 trial.

Childhood adiposity could predict future polycystic ovary syndrome in girls, according to a study published in Pediatrics.